Skip to main content

Table 1 Baseline characteristics of included randomized controlled trials

From: Glucagon-like peptide-1 receptor agonists and heart failure in type 2 diabetes: systematic review and meta-analysis of randomized and observational studies

Study

International study

Number of countries involved

Number of study sites

Study phase

Total number of patients randomized

Length of follow up (weeks)

Male (n,%)

Mean age (years)

Mean BMI (kg/m2)

Mean HbA1c (%)

Mean FPG (mmol/L)

Mean diabetes duration (years)

Trials reporting heart failure

 Inagaki 2012 [38, 39]

No

1

NR

III

427

26

290 (67.9)

56.8

26.1

8.5

NR

9.0

 NCT00294723 2010 [40, 41]

Yes

2

138

III

746

104

371 (49.7)

53.0

33.1

8.3

9.4

5.4

 NCT00318461 2010 [42–44]

Yes

21

170

III

1091

104

635 (58.2)

56.7

31.0

8.4

10.0

7.6

 NCT00360334 2009 [45]

No

1

35

III

235

26

160 (68.4)

56.6

NR

NR

NR

6.0

 NCT00614120 2010 [46]

Yes

3

51

III

929

16

514 (55.3)

53.3

25.6

NR

NR

7.5

 NCT00701935 2013 [47]

Yes

2

17

II

80

26

42 (52.5)

58.1

NR

NR

NR

NR

 NCT00838903 2014 [48, 49]

Yes

10

289

III

1049

164

482 (47.6)

54.5

32.6

8.1

9.2

6.0

 NCT00838916 2014 [50, 51]

Yes

4

222

III

779

164

418 (56.1)

55.5

33.1

8.3

9.5

8.8

 NCT00839527 2014 [52]

Yes

9

358

III

685

164

353 (53.2)

55.2

NR

NR

NR

NR

 NCT00849017 2014 [53]

Yes

3

262

III

309

164

166 (55.1)

52.9

NR

NR

NR

NR

 NCT00849056 2014 [54]

Yes

6

331

III

310

156

180 (59.8)

55.0

NR

NR

NR

NR

 NCT00855439 2015 [55]

No

1

1

NR

46

82

26 (56.5)

53.0

NR

NR

NR

NR

 NCT00960661 2013 [56, 57]

Yes

17

108

III

637

30

261 (51.2)

59.5

32.5

8.2

7.1

11.5a

 NCT01064687 2015 [58]

Yes

3

89

III

978

26

570 (58.4)

55.7

33.2

8.1

9.0

8.8

 NCT01075282 2015 [59]

Yes

20

78

III

810

78

353 (51.3)

56.7

31.6

8.1

9.1

9.1

 NCT01126580 2015 [60, 61]

Yes

19

91

III

807

56

353 (43.7)

55.6

33.3

7.6

9.0

2.6

 NCT01191268 2014 [62]

Yes

16

101

III

884

52

473 (53.5)

59.4

32.5

8.5

NR

12.7

 NCT01512108 2014 [63]

No

1

36

III

363

52

262 (72.8)

59.5

NR

8.1

8.8

NR

 NCT01620489 2014 [64]

Yes

6

50

III

277

26

140 (50.5)

67.2

NR

NR

NR

NR

 Pratley 2013 [65]

Yes

17

130

III

760

24

362 (48.9)

56.4

32.7

8.3

10.0

8.8

Trials reporting hospitalization for heart failure

 Bentley-Lewis 2015 (ELIXA) [15, 16]

Yes

49

NR

III

6068

108b

4207 (69.3)

60.3

30.2

7.7

8.2

9.3

  1. BMI body mass index, FPG fasting plasma glucose, NR not reported
  2. amedian diabetes duration (years); bmedian follow up time (weeks)